Literature DB >> 16686806

Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II.

Luther T Clark1, Kevin C Maki, Ron Galant, David J Maron, Thomas A Pearson, Michael H Davidson.   

Abstract

BACKGROUND: African Americans (AA) have the highest coronary heart disease mortality rate of any ethnic group in the United States. Data from the National Cholesterol Education Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey were used to assess ethnic differences in low-density lipoprotein cholesterol (LDL-C) goal achievement.
METHODS: NEPTUNE II surveyed patients with treated dyslipidemia to assess achievement of treatment goals established by the Adult Treatment Panel III of the National Cholesterol Education Program. United States physicians working in primary care or relevant subspecialties enrolled 10 to 20 consecutive patients (May to September 2003), and patient data were recorded in Personal Digital Assistants and uploaded to a central database via the internet.
RESULTS: Among 4,885 patients receiving treatment for dyslipidemia, 79.7% were non-Hispanic white (NHW) and 8.4% were AA. Non-Hispanic white and AA patients had significantly different frequencies of treatment success, with 69.0% and 53.7%, respectively, having achieved their LDL-C goal (P<.001). African-American patients were more likely to be in the highest risk category, and less likely to be using lipid drug therapy, taking high-efficacy statins, and receiving care from a subspecialist, but the difference in goal achievement remained significant (P<.001) after adjustment for these and other predictors of treatment success.
CONCLUSIONS: The frequency of treatment success in dyslipidemia management was significantly lower in AA than NHW patients. Additional research is needed to elucidate reasons for this disparity and to evaluate strategies for improving goal achievement among AA patients receiving therapy for dyslipidemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16686806      PMCID: PMC1484721          DOI: 10.1111/j.1525-1497.2006.00349.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  17 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Racial differences in adherence to cardiac medications.

Authors:  Hyasmine Charles; Chester B Good; Barbara H Hanusa; Chung-Chou H Chang; Jeff Whittle
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

4.  Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.

Authors:  Marcus L Williams; Michael T Morris; Umad Ahmad; Manal Yousseff; Win Li; Norman Ertel
Journal:  Ethn Dis       Date:  2002       Impact factor: 1.847

5.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Authors:  Michael H Davidson; Kevin C Maki; Thomas A Pearson; Richard C Pasternak; Prakash C Deedwania; James M McKenney; Gregg C Fonarow; David J Maron; Benjamin J Ansell; Luther T Clark; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2005-08-15       Impact factor: 2.778

6.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

Review 7.  Coronary heart disease in African Americans.

Authors:  L T Clark; K C Ferdinand; J M Flack; J R Gavin; W D Hall; S K Kumanyika; J W Reed; E Saunders; H A Valantine; K Watson; N K Wenger; J T Wright
Journal:  Heart Dis       Date:  2001 Mar-Apr

Review 8.  Coronary heart disease and lipid-modifying treatment in African American patients.

Authors:  Keith C Ferdinand
Journal:  Am Heart J       Date:  2004-05       Impact factor: 4.749

9.  Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study.

Authors:  J C LaRosa; W Applegate; J R Crouse; D B Hunninghake; R Grimm; R Knopp; J H Eckfeldt; C E Davis; D J Gordon
Journal:  Arch Intern Med       Date:  1994-03-14

10.  Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years.

Authors:  J D Neaton; L H Kuller; D Wentworth; N O Borhani
Journal:  Am Heart J       Date:  1984-09       Impact factor: 4.749

View more
  8 in total

1.  Trends in cardiovascular risk factor levels in the Minnesota Heart Survey (1980-2002) as compared with the National Health and Nutrition Examination Survey (1976-2002): A partial explanation for Minnesota's low cardiovascular disease mortality?

Authors:  Huifen Wang; Lyn M Steffen; David R Jacobs; Xia Zhou; Henry Blackburn; Alan K Berger; Kristian B Filion; Russell V Luepker
Journal:  Am J Epidemiol       Date:  2011-01-27       Impact factor: 4.897

Review 2.  Cardiovascular health disparities: a systematic review of health care interventions.

Authors:  Andrew M Davis; Lisa M Vinci; Tochi M Okwuosa; Ayana R Chase; Elbert S Huang
Journal:  Med Care Res Rev       Date:  2007-10       Impact factor: 3.929

3.  Racial differences in medication adherence: A cross-sectional study of Medicare enrollees.

Authors:  Ben S Gerber; Young Ik Cho; Ahsan M Arozullah; Shoou-Yih D Lee
Journal:  Am J Geriatr Pharmacother       Date:  2010-04

4.  Association between Statin Use and Risk of Parkinson's Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals.

Authors:  Chieh-Chen Wu; Md Mohaimenul Islam; An-Jen Lee; Chun-Hsien Su; Yung-Ching Weng; Chih-Yang Yeh; Hsun-Hua Lee; Ming-Chin Lin
Journal:  J Pers Med       Date:  2022-05-19

5.  Addressing Stroke Risk Factors in Black and White Americans: Findings from the National Health and Nutrition Examination Survey, 2009-2010.

Authors:  Karen C Albright; Amelia K Boehme; Rikki M Tanner; Justin Blackburn; George Howard; Virginia J Howard; Monika Safford; T Mark Beasley; Nita Limdi
Journal:  Ethn Dis       Date:  2016-01-21       Impact factor: 1.847

6.  Racial disparities in lipid control in patients with diabetes.

Authors:  Darcy Saffar; Keoki Williams; Jennifer Elston Lafata; George Divine; Manel Pladevall
Journal:  Am J Manag Care       Date:  2012-06       Impact factor: 2.229

7.  Statin Use and the Risk of Parkinson's Disease: An Updated Meta-Analysis.

Authors:  Shuang Bai; Yi Song; Xin Huang; Lidan Peng; Jie Jia; Yu Liu; Hong Lu
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

8.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress.

Authors:  Camille B Carroll; Richard K H Wyse
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.